Encorafenib + cetuximab (EC) BREAKWATER Study Reveals Breakthrough in Treating BRAF V600E-Mutant Metastatic Colorectal Cancer
Exciting findings from the BREAKWATER study: encorafenib and cetuximab combination therapy improves treatment outcomes for patients with BRAF V600E-mutant metastatic colorectal cancer.